BRIEF—Upsher-Smith gains rights to ophthalmic ANDAs

Upsher-Smith Laboratories today announced that it has entered into an exclusive agreement with a pharmaceutical partner to market and distribute a group of six ophthalmic and otic Abbreviated New Drug Application (ANDA) products with combined annual sales of more than $1.6 billion (IQVIA, 12 months ending March 2018).

This collaboration is part of Upsher-Smith's company-wide effort to grow its generics pipeline and to expand its strategic relationships within the pharmaceutical industry.

Under the terms of the agreement, Upsher-Smith will register the products with the US Food and Drug Administration and market and distribute them under its own label in the USA upon FDA approval.

The unnamed partner company will develop and manufacture the products exclusively for Upsher-Smith, which was acquired earlier this year by Sawai Pharmaceutical. Financial terms related to that deal have not been disclosed.

"Upsher-Smith is committed to significantly expanding its pipeline and diversifying its product portfolio through both internal development and strategic partnerships," said Rusty Field, president and chief executive, Upsher-Smith.